Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lowy

Showing results (351-360 of 401) with videos related to

Pageof 41
Sort By:
Blood|March 6, 2010
The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1Maria de la Luz Sierra, Shuhei Sakakibara, Paola Gasperini, et al.
The Journal of Infectious Diseases|July 11, 2003
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesLigia A Pinto, Jessica Edwards, Philip E Castle, et al.
Vaccine|February 17, 2025
Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT)Mónica S Sierra, Loretto J Carvajal, Peter Dull, et al.
Vaccine|April 28, 2005
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole bloodLigia A Pinto, Philip E Castle, Richard B Roden, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2001
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse)S K Kjaer, B Chackerian, A J van den Brule, et al.
Journal of the National Cancer Institute|February 22, 2001
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccineC D Harro, Y Y Pang, R B Roden, et al.
Cancer Discovery|May 16, 2012
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa RicaRolando Herrero, Sholom Wacholder, Ana C Rodríguez, et al.
Journal of the National Cancer Institute|September 13, 2011
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineAimée R Kreimer, Ana Cecilia Rodriguez, Allan Hildesheim, et al.
Nature Communications|December 4, 2021
Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor proteinBrajendra K Tripathi, Meghan F Anderman, Disha Bhargava, et al.
Journal of Virology|March 29, 2013
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccineSubhashini Jagu, Kihyuck Kwak, John T Schiller, et al.
Pageof 41

Showing results (351-360 of 401) with videos related to

Sort By:
Pageof 41
Blood|March 6, 2010
The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1Maria de la Luz Sierra, Shuhei Sakakibara, Paola Gasperini, et al.
The Journal of Infectious Diseases|July 11, 2003
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particlesLigia A Pinto, Jessica Edwards, Philip E Castle, et al.
Vaccine|February 17, 2025
Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT)Mónica S Sierra, Loretto J Carvajal, Peter Dull, et al.
Vaccine|April 28, 2005
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole bloodLigia A Pinto, Philip E Castle, Richard B Roden, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2001
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse)S K Kjaer, B Chackerian, A J van den Brule, et al.
Journal of the National Cancer Institute|February 22, 2001
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccineC D Harro, Y Y Pang, R B Roden, et al.
Cancer Discovery|May 16, 2012
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa RicaRolando Herrero, Sholom Wacholder, Ana C Rodríguez, et al.
Journal of the National Cancer Institute|September 13, 2011
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineAimée R Kreimer, Ana Cecilia Rodriguez, Allan Hildesheim, et al.
Nature Communications|December 4, 2021
Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor proteinBrajendra K Tripathi, Meghan F Anderman, Disha Bhargava, et al.
Journal of Virology|March 29, 2013
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccineSubhashini Jagu, Kihyuck Kwak, John T Schiller, et al.
Pageof 41